- Home
- EFSI vs PROK Comparison
EFSI vs PROK Comparison
Compare EFSI & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFSI
- PROK
- Stock Information
- Founded
- EFSI 1881
- PROK 2015
- Country
- EFSI United States
- PROK United States
- Employees
- EFSI N/A
- PROK N/A
- Industry
- EFSI Major Banks
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EFSI Finance
- PROK Health Care
- Exchange
- EFSI Nasdaq
- PROK Nasdaq
- Market Cap
- EFSI 161.4M
- PROK 129.5M
- IPO Year
- EFSI N/A
- PROK N/A
- Fundamental
- Price
- EFSI $29.50
- PROK $0.68
- Analyst Decision
- EFSI Strong Buy
- PROK Buy
- Analyst Count
- EFSI 2
- PROK 3
- Target Price
- EFSI $40.00
- PROK $4.50
- AVG Volume (30 Days)
- EFSI 22.9K
- PROK 754.3K
- Earning Date
- EFSI 04-25-2025
- PROK 08-08-2025
- Dividend Yield
- EFSI 4.20%
- PROK N/A
- EPS Growth
- EFSI N/A
- PROK N/A
- EPS
- EFSI 1.52
- PROK N/A
- Revenue
- EFSI $58,067,000.00
- PROK $306,000.00
- Revenue This Year
- EFSI $3.16
- PROK $54.34
- Revenue Next Year
- EFSI $22.35
- PROK N/A
- P/E Ratio
- EFSI $19.38
- PROK N/A
- Revenue Growth
- EFSI N/A
- PROK N/A
- 52 Week Low
- EFSI $28.70
- PROK $0.46
- 52 Week High
- EFSI $36.93
- PROK $2.59
- Technical
- Relative Strength Index (RSI)
- EFSI N/A
- PROK 40.03
- Support Level
- EFSI N/A
- PROK $0.61
- Resistance Level
- EFSI N/A
- PROK $0.73
- Average True Range (ATR)
- EFSI 0.00
- PROK 0.12
- MACD
- EFSI 0.00
- PROK -0.03
- Stochastic Oscillator
- EFSI 0.00
- PROK 7.73
About EFSI Eagle Financial Services Inc Common Stock
Eagle Financial Services Inc is a locally owned and managed financial institution. It offers retail and commercial banking services, including demand, savings and time deposits and consumer, mortgage, and commercial loans. It also offers telephone banking, internet banking, and mobile banking to its customers. The Company has three reportable operating segments, Community Banking, Marine Lending and Wealth Management. It generates a majority of its revenue from the Community Banking segment.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.